Immunic Number Of Shares Shorted vs. Net Income
| IMUX Stock | USD 1.37 -0.08 -5.52% |
This section tracks how Immunic profitability aligns with revenue trends, asset use, and equity returns.
Risk vs Return Analysis. Macro event markers
Market capitalization and book value offer complementary views of Immunic — the first driven by investor sentiment, the second by accounting standards. Immunic's market capitalization is 178.74 M. With a P/B ratio of 12.72, the market values Immunic well above its book equity. Enterprise value stands at 174.27 M. Intrinsic value reflects what Immunic's fundamentals imply about worth, which may differ from both the trading price and the book figure. Analytical frameworks help reconcile those views.
Value and price for Immunic are related but not identical, and they can diverge across cycles. For Immunic, key inputs include a P/B ratio of 12.72, and ROE of -16.53%. The quoted price is simply the exchange level where supply meets demand.
Immunic Net Income vs. Number Of Shares Shorted Fundamental Analysis
Peer multiple analysis evaluates Immunic's pricing efficiency within its industry. Immunic is rated third in number of shares shorted among leading competitors. It is rated below average in net income among leading competitors . Recent disclosures position Net Loss within a retreating cycle. The preceding year’s Net Loss stood at -97.17 Million. Sector-based multiples assess Immunic's pricing discipline.Immunic Net Income vs. Number Of Shares Shorted
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Immunic |
| = | 7.58 M |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Immunic |
| = | -97.17 M |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Immunic Net Income Comparison
Immunic is currently under evaluation in net income among leading competitors.
Immunic Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Immunic, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Immunic will eventually generate negative long term returns. The profitability progress is the general direction of Immunic's change in net profit over the period of time. It can combine multiple indicators of Immunic, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 2.6 M | 2.8 M | |
| Operating Income | -103.2 M | -98.1 M | |
| Income Before Tax | -97.2 M | -92.3 M | |
| Total Other Income Expense Net | 6.1 M | 6.4 M | |
| Net Loss | -97.2 M | -92.3 M | |
| Income Tax Expense | -90.5 M | -85.9 M | |
| Net Loss | -97.2 M | -102 M | |
| Non Operating Income Net Other | -827.1 K | -785.7 K | |
| Net Loss | -108.4 M | -102.9 M | |
| Interest Income | 1 M | 1 M | |
| Net Interest Income | 1 M | 1.1 M | |
| Change To Netincome | 52.5 M | 55.1 M | |
| Net Loss | -0.06 | -0.07 | |
| Income Quality | 0.88 | 1.02 | |
| Net Income Per E B T | 0.90 | 0.80 |
Immunic Profitability Driver Comparison
Understanding the profitability drivers of Immunic helps investors assess the sustainability of its earnings over time. Unexpected events - including tax changes, commodity price movements, and macroeconomic disruptions - can significantly impact Immunic's long-term profit trajectory.
Earnings per Share Projection vs Actual
Use Immunic in pair-trading
Pair trading with Immunic can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.
Immunic Pair Trading
Immunic Pair Trading Analysis
Portfolio managers use rolling correlation data for Immunic to assess whether candidate substitutes for Immunic are stable or episodically correlated. Stable, long-run correlations provide more reliable wash-sale substitutes.
High-frequency correlation analysis for Immunic uses intraday price data to capture short-term co-movements that may differ from daily or monthly correlation estimates. This is particularly relevant for short-term Immunic trading strategies.
Pair evaluation and Correlation analysis for Immunic provide hedging context. The context can be applied within sectors, industries, or broader universes.Use Investing Themes to Complement your Immunic position
Using Immunic inside a theme workflow gives investors a structured way to compare related stocks, funds, ETFs, and crypto assets before allocating capital. The practical benefit is that the selected idea can be tuned either for higher upside or for tighter risk control.
Did You Try This Idea?
Run Cancer Fighters Thematic Idea Now
Cancer Fighters
Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. The Cancer Fighters theme has 60 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cancer Fighters Theme or any other thematic opportunities.
| View All Next | Launch |
More Resources for Immunic Stock Analysis
A structured review of Immunic often starts with core financial statements and trend context. Ratio context helps frame profitability, efficiency, and growth trends for Immunic Stock. Below are reports that help frame Immunic Stock in context:Risk vs Return Analysis. For a practical introduction to investing in Immunic Stock, check out our How to Buy Immunic guide.Analysis related to Immunic should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Profitability projection for Immunic starts with historical financial statements. Core statements include the income statement, balance sheet, and cash-flow statement.